Discover how XPC protein collaborates with MDM2 to degrade p53 tumor suppressor, revealing new insights into cancer mechanisms and potential therapies.
Discover how the stress protein ATF3 acts as a molecular double agent, stabilizing p53 by competing with MDM2 to fight cancer development.
Explore how mutations in the MDM2 protein can subvert the body's natural cancer defenses and contribute to tumor development.
Discover how PROTAC molecular technology is revolutionizing leukemia treatment by degrading cancer-causing proteins with unprecedented efficacy.
Discover how a 13-gene signature predicts response to MDM2 inhibitors in p53 wild-type cancers, enabling personalized therapy approaches.